Juan Rodríguez-Silverio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Juan Rodríguez-Silverio has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cindy Karel Arregoitia-Sarabia
Escuela Nacional de Ciencias Biológicas IPN. Unidad Profesional Lázaro Cárdenas, Ciudad de México, México
1 shared publication - Diana E Galván-Hernández
University of the Army and Air Force, Secretary of National Defense, Military Graduate School of Health, 11200, Mexico
1 shared publication - Eduardo Beltrán-Sarmiento
Hospital Militar, Secretaría de la Defensa Nacional, Mexico City, Mexico
1 shared publication - Eduardo Ramos-Reyna
University of the Army and Air Force, Secretary of National Defense, Military Graduate School of Health, 11200, Mexico
1 shared publication - Elvia Coballase-Urrutia
Laboratorio de Farmacología, Instituto Nacional de Pediatría, Mexico City 04530, Mexico
1 shared publication - Esaú Floriano-Sánchez
University of the Army and Air Force, Secretary of National Defense, Military Graduate School of Health, 11200, Mexico
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Vol. 64 (1) , e6807
[Rh blood group: Review and importance of genotyping].
Rh antigen is a transmembrane protein whose presence or absence is genetically inherited in humans. The genetic expression is controlled by 2 closely linked genes. The expression of the group (the antigen) can be modified by mutations or deletions in the gene that encodes it, leading to discrepancies that can sometimes only be resolved with molecular testing; such is the case of people with weak or partial expression of the D antigen. Since the antibodies of Rh blood group are not spontaneous and are linked to both the possibility of developing hemolytic disease of the newborn and severe transfusion reactions, the administration of anti-D immunoglobulin has been implemented as a risk reduction measure. In developed countries, genotyping methods are used to guide the administration of this vaccine, since, as a product of human origin, its availability is often not the same in all areas where it is required. Understanding the characteristics that distinguish the antigens of this blood group helps us move toward the use of higher-resolution determination methods that allow us to increase blood safety in our patients.
- 1 January 2025
- Vol. 64 (1) , e6807
Open Access[Rh blood group: Review and importance of genotyping].
Rh antigen is a transmembrane protein whose presence or absence is genetically inherited in humans. The genetic expression is controlled by 2 closely linked genes. The expression of the group (the antigen) can be modified by mutations or deletions in the gene that encodes it, leading to discrepancies that can sometimes only be resolved with molecular testing; such is the case of people with weak or partial expression of the D antigen. Since the antibodies of Rh blood group are not spontaneous and are linked to both the possibility of developing hemolytic disease of the newborn and severe transfusion reactions, the administration of anti-D immunoglobulin has been implemented as a risk reduction measure. In developed countries, genotyping methods are used to guide the administration of this vaccine, since, as a product of human origin, its availability is often not the same in all areas where it is required. Understanding the characteristics that distinguish the antigens of this blood group helps us move toward the use of higher-resolution determination methods that allow us to increase blood safety in our patients.
- Open Access
- 2 October 2023
- Vol. 61 (Suppl 3) , S363-S371
Características de los pacientes con esclerosis sistémica que desarrollan enfermedad pulmonar intersticial
La enfermedad pulmonar intersticial (EPI) está relacionada a una mayor mortalidad en esclerosis sistémica (ES). Los factores asociados a su presentación han mostrado variabilidad en diferentes poblaciones. Pocos estudios se han realizado en mestizos mexicanos. analizar los factores clínicos y paraclínicos asociados a EPI en pacientes con ES. estudio retrospectivo de casos y controles en el que se incluyeron pacientes > 18 años con diagnóstico de ES, según criterios EULAR/ACR 2013 y EPI por capacidad vital forzada (CVF) < 70% y > 5% de área pulmonar efectada en tomografía. La fuerza de asociación de los factores para EPI se midió por razón de momios (RM) con intervalos de confianza del 95% (IC95%). Las variables significativas se analizaron por regresión logística múltiple con ajuste. de los 80 pacientes con ES, 38 (47.5%) tenían EPI. Factores de riesgo como tabaquismo, mayor índice de actividad, menor CVF, anticuerpos antitopoisomerasa I y factores protectores como variedad limitada de ES, patrón capilaroscópico temprano y anticuerpos anticentrómero estuvieron asociados a EPI. En el análisis multivariado un mayor índice de actividad con RM 4.17, (IC95%: 2.01-8.65) persistió como un factor de riesgo; en cambio, los anticuerpos anticentrómero con RM 0.17, (IC95%: 0.03-0.85) persistieron como un factor protector asociado a EPI. un mayor índice de actividad y la presencia anticuerpos anticentrómero persistieron como factores asociados a la presencia de EPI en ES.
- 2 October 2023
- Vol. 61 (Suppl 3) , S363-S371
Open AccessCaracterísticas de los pacientes con esclerosis sistémica que desarrollan enfermedad pulmonar intersticial
La enfermedad pulmonar intersticial (EPI) está relacionada a una mayor mortalidad en esclerosis sistémica (ES). Los factores asociados a su presentación han mostrado variabilidad en diferentes poblaciones. Pocos estudios se han realizado en mestizos mexicanos. analizar los factores clínicos y paraclínicos asociados a EPI en pacientes con ES. estudio retrospectivo de casos y controles en el que se incluyeron pacientes > 18 años con diagnóstico de ES, según criterios EULAR/ACR 2013 y EPI por capacidad vital forzada (CVF) < 70% y > 5% de área pulmonar efectada en tomografía. La fuerza de asociación de los factores para EPI se midió por razón de momios (RM) con intervalos de confianza del 95% (IC95%). Las variables significativas se analizaron por regresión logística múltiple con ajuste. de los 80 pacientes con ES, 38 (47.5%) tenían EPI. Factores de riesgo como tabaquismo, mayor índice de actividad, menor CVF, anticuerpos antitopoisomerasa I y factores protectores como variedad limitada de ES, patrón capilaroscópico temprano y anticuerpos anticentrómero estuvieron asociados a EPI. En el análisis multivariado un mayor índice de actividad con RM 4.17, (IC95%: 2.01-8.65) persistió como un factor de riesgo; en cambio, los anticuerpos anticentrómero con RM 0.17, (IC95%: 0.03-0.85) persistieron como un factor protector asociado a EPI. un mayor índice de actividad y la presencia anticuerpos anticentrómero persistieron como factores asociados a la presencia de EPI en ES.
- Open Access
- 1 January 2018
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2018 (1) , 7954371
Effects of Valproate Monotherapy on the Oxidant‐Antioxidant Status in Mexican Epileptic Children: A Longitudinal Study
Epilepsy is a neurological disorder that can produce brain injury and neuronal death. Several factors such as oxidative stress have been implicated in epileptogenesis. Valproic acid (VPA) is a widely used drug for the treatment of epilepsy, but the mechanisms underlying these benefits are complex and still not fully understood. The objective of this study was to evaluate, for the first time, the effects of VPA on the oxidant‐antioxidant status in Mexican epileptic children before and after 6 or 12 months of treatment with VPA by determining the activities of several plasmatic antioxidant enzymes (glutathione reductase (GR), glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT)) and oxidant marker (malondialdehyde (MDA), hydrogen peroxide (H2O2), 8‐hydroxy‐2‐deoxyguanosine (8‐OHdG), and 3‐nitrotyrosine (3‐NT) levels) profiles. The possible relationships between these markers and some clinicopathological factors were also evaluated. Plasma samples were obtained from the peripheral blood of 16 healthy children and 32 patients diagnosed with epilepsy, and antioxidant/oxidant markers were measured spectrometrically. Significant decreases in all antioxidant enzyme activities, with the exception of GPx, and increases in all oxidant markers in epileptic subjects versus healthy children were observed. Interestingly, all these effects reverted after VPA monotherapy, although the results were different depending on the treatment period (6 or 12 months). These changes were contingent upon brain imaging findings, type of epilepsy, etiology of epilepsy, and the efficacy of 6 months of VPA monotherapy. Significant and positive correlations of GPx and SOD activities and H2O2 and 8‐OHdG levels with the age of children at the beginning of treatment were observed. H2O2 levels were also positively correlated with number of seizures before VPA monotherapy. VPA showed significant antioxidant effects decreasing seizure activity, possibly depending on the presence of cerebral structural alterations, treatment time, and age.
- 1 January 2018
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2018 (1) , 7954371
Open AccessEffects of Valproate Monotherapy on the Oxidant‐Antioxidant Status in Mexican Epileptic Children: A Longitudinal Study
Epilepsy is a neurological disorder that can produce brain injury and neuronal death. Several factors such as oxidative stress have been implicated in epileptogenesis. Valproic acid (VPA) is a widely used drug for the treatment of epilepsy, but the mechanisms underlying these benefits are complex and still not fully understood. The objective of this study was to evaluate, for the first time, the effects of VPA on the oxidant‐antioxidant status in Mexican epileptic children before and after 6 or 12 months of treatment with VPA by determining the activities of several plasmatic antioxidant enzymes (glutathione reductase (GR), glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT)) and oxidant marker (malondialdehyde (MDA), hydrogen peroxide (H2O2), 8‐hydroxy‐2‐deoxyguanosine (8‐OHdG), and 3‐nitrotyrosine (3‐NT) levels) profiles. The possible relationships between these markers and some clinicopathological factors were also evaluated. Plasma samples were obtained from the peripheral blood of 16 healthy children and 32 patients diagnosed with epilepsy, and antioxidant/oxidant markers were measured spectrometrically. Significant decreases in all antioxidant enzyme activities, with the exception of GPx, and increases in all oxidant markers in epileptic subjects versus healthy children were observed. Interestingly, all these effects reverted after VPA monotherapy, although the results were different depending on the treatment period (6 or 12 months). These changes were contingent upon brain imaging findings, type of epilepsy, etiology of epilepsy, and the efficacy of 6 months of VPA monotherapy. Significant and positive correlations of GPx and SOD activities and H2O2 and 8‐OHdG levels with the age of children at the beginning of treatment were observed. H2O2 levels were also positively correlated with number of seizures before VPA monotherapy. VPA showed significant antioxidant effects decreasing seizure activity, possibly depending on the presence of cerebral structural alterations, treatment time, and age.